Clinical trials: Schizophrenia Spectrum Disorders
Prodromal Schizophrenia, Psychotic Disorders
Psychosis: Early Detection, Intervention and Prevention
The primary aim of this application is to conduct a randomized, controlled clinical trial of a specialized mental health service delivery system specifically developed for prodromal psychotic disorders.
- Conditions
- Prodromal Schizophrenia, Psychotic Disorders, Severe Bipolar Disorder With Psychotic Features, Severe Major Depression With Psychotic Features
- Trial name
- EDIP (NCT01597141)
- Testing
- Family-aided Assertive Community Treatment, Enhanced standard treatment
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- MaineHealth
Schizophrenia
A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.
A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. This study is accepting male and female participants between 18 years old -65 years old who have been…
- Trial name
- NCT04115319
- Testing
- SEP363856, quetiapine XR
- Where
- 42 sites in United States, Romania and 2 more
- Volunteers
- 305 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson
Schizophrenia, Schizoaffective Disorder
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation
The purpose of this study is to determine whether the administration of omega-3 polyunsaturated fatty acids, particularly eicosapentaenoic acid (EPA), can be useful both to reduce coronary artery disease (CAD) risk and illness…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder
- Trial name
- CAD (NCT00167310)
- Testing
- Eicosapentaenoic acid (omega-3 fatty acid)
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Depression
Quetiapine Extended Release Depression Symptoms
Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia.
- Trial name
- ExAttitude (NCT00640562)
- Testing
- Quetiapine Extended Release, Risperidone
- Where
- 21 sites in Italy
- Volunteers
- 216 people
- Sponsor
- AstraZeneca
Psychotic Disorders, Psychosis
Pilot Study of Motivational Interviewing for Loved Ones
The study population for this research will include parents and concerned significant others (PCSO) of individuals experiencing recent (past five years) onset of a psychotic disorder (hereafter referred to as individuals with…
- Conditions
- Psychotic Disorders, Psychosis, Psychotic Episode
- Trial name
- MILO-Pilot (NCT04010747)
- Testing
- Motivational Interviewing for Loved Ones (MILO), Mental Health Services Consultation and Waitlist
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Boston Medical Center
Schizophrenia, Schizo Affective Disorder
Brain Stimulation and Cognitive Training - Efficacy
People with serious mental illness often experience difficulties with thinking skills like memory. These difficulties can make it harder to perform day-to-day activities.
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder
- Trial name
- NCT05111548
- Testing
- tDCS (Active), BrainHQ, tDCS (Inactive)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Michigan
Psychotic Disorder
Yoga and Aerobic Exercise in Psychosis
The current study aims to evaluate the impacts of yoga and aerobic exercise on neuro-cognitive function, symptoms and brain changes in early psychosis.
- Trial name
- YEP (NCT01207219)
- Testing
- Yoga therapy, Aerobic exercise
- Where
- Hong Kong
- Volunteers
- 140 people
- Sponsor
- The University of Hong Kong
Schizophrenia, Schizoaffective Disorder
Cannabidiol Treatment in Patients With Early Psychosis
Cannabidiol (CBD) is a component of herbal cannabis that is present in varying concentrations in cannabis extracts. CBD has been shown to produce central effects including hypnotic, anticonvulsive, anxiolytic and neuroprotective…
- Trial name
- CBD (NCT02504151)
- Testing
- Cannabidiol
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Schizophrenia, Schizoaffective Disorder
Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia
The aim of this study was to compare the efficacy and safety of intramuscular 10 mg olanzapine versus intramuscular 5 mg haloperidol plus lorazepam 2 mg in the treatment of acute agitated schizophrenic patients of Taiwanese…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Agitation
- Trial name
- NCT00797277
- Testing
- IM olanzapine, IM haloperidol plus lorazepam
- Where
- Taiwan
- Volunteers
- 67 people
- Sponsor
- National Taiwan University Hospital
Schizophrenia, Major Depression
Past Pain Experience and Perception of Experimental Pain
Differences in pain perception between subjects with and without psychiatric illness may be influenced by the individual experience, and not primarily by the pathology, although the pathological frame may amplify it.The aim of…
- Trial name
- NCT01575912
- Testing
- experimental pain tests
- Where
- France
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Esquirol
Schizophrenia
Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia
To evaluate the safety and tolerability of the long-term treatment with Lu AF35700.
- Trial name
- Debut (NCT02892422)
- Testing
- Lu AF35700
- Where
- 102 sites in United States, Bulgaria and 11 more
- Volunteers
- 528 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Schizoaffective Disorder
Nicotinic Receptors and Schizophrenia
The investigators hypothesize that sustained-release DMXB-A-SR (3-2,4 dimethoxybenzylidene anabaseine sustained release) will provide clinical improvement in cognition in patients with schizophrenia who are smokers and who are…
- Trial name
- NCT01400477
- Testing
- DMXB-A-SR
- Where
- 2 sites in United States
- Volunteers
- 97 people
- Sponsor
- University of Colorado, Denver
Psychotic Disorders, Veterans
Impact of VVV Group for Veterans With SMI
Veterans with Serious Mental Illness (SMI) struggle with social integration - participation in work, housing, and citizenship - due to symptoms, stigma, and psychosocial challenges.
- Trial name
- VVV (NCT05562674)
- Testing
- Veteran Voices and Visions
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- VA Office of Research and Development
Schizophrenia, Schizoaffective Disorder
Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia
This study will determine the comparative effectiveness of two systems designed to improve medication adherence in people with schizophrenia.
- Trial name
- NCT00406718
- Testing
- Med-eMonitor, PharmCAT, Treatment as Usual
- Where
- United States
- Volunteers
- 197 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia
A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot
This study will evaluate the safety, tolerability, efficacy and pharmacokinetics of aripiprazole intramuscular (IM) depot multiple doses every 4 weeks in adult patients with schizophrenia.
- Trial name
- NCT01870999
- Testing
- aripiprazole IM depot, aripiprazole tablets
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia
The purpose of this 6 month study is to compare the metabolic effects of paliperidone ER and olanzapine in patients with schizophrenia, using the ratio of the concentration of lipids (triglycerides (TG)) in the blood to the…
- Trial name
- NCT00645099
- Testing
- olanzapine, paliperidone ER
- Where
- 46 sites in Argentina, Egypt and 12 more
- Volunteers
- 462 people
- Sponsor
- Janssen-Cilag International NV
Schizophrenia
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adults With Schizophrenia
The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
- Trial name
- NCT04158687
- Testing
- CTP-692
- Where
- 26 sites in United States
- Volunteers
- 326 people
- Sponsor
- Concert Pharmaceuticals
Schizophrenia
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
The primary objective of the current study is to investigate the safety and tolerability of BI 409306 in schizophrenic patients following oral administration of multiple low, medium, and high doses over 14 days.
- Trial name
- NCT01892384
- Testing
- BI 409306
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Intranasal Insulin Treatment in Patients With Schizophrenia
This study is an 8-week, randomized, double-blind, placebo-controlled trial of intranasal insulin as an adjunctive therapy, with a 4-week follow-up, in 60 non-diabetic schizophrenia subjects to examine insulin's effect on…
- Trial name
- NCT00575666
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Massachusetts, Worcester